ALVO
NASDAQ · Biotechnology
Alvotech Sa
$5.95
+0.07 (+1.19%)
Open$5.87
Previous Close$5.88
Day High$5.98
Day Low$5.82
52W High$9.25
52W Low$2.94
Volume—
Avg Volume1.05M
Market Cap2.09B
P/E Ratio—
EPS$-0.63
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+433.1% upside
Current
$5.95
$5.95
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 719.94M | 377.68M | 133.98M |
| Net Income | 34.12M | 16.11M | 26.13M |
| Profit Margin | 4.7% | 4.5% | 19.5% |
| EBITDA | 146.42M | 72.97M | 43.53M |
| Free Cash Flow | — | — | 33.36M |
| Rev Growth | +90.6% | +90.6% | +20.0% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |